Evaluation of Neointimal Coverage of Everolimus-Eluting Stent and Bare-metal Stent After Implantation in STEMI Patients by Optical Coherence Tomography
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2018
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction
- Focus Therapeutic Use
- Acronyms HMUOCT-STEMI; NeoCover
- 09 Dec 2016 Planned End Date changed from 1 Dec 2014 to 1 May 2017.
- 09 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Jul 2013 New trial record